Company Research Report: Daiichi Sankyo Europe GmbH

Company Overview

Name: Daiichi Sankyo Europe GmbH

Mission: Create innovative pharmaceuticals addressing diverse medical needs, contributing to the enrichment of quality of life. Their vision for 2030 is to become an innovative Global Healthcare Company Contributing to the Sustainable Development of Society.

Founded: The company was founded in 2006 through the merger of well-established Japanese companies Daiichi and Sankyo.

Key People:

Managing Director: Masahiro Kato

Chairman of Supervisory Board: Tetsuya Ohira

Headquarters:

Global: Tokyo, Japan

European: Munich, Germany

Number of Employees: Approximately 2,500 employees in Europe.

Revenue: No information is available.

Recognition: Known as a global pharmaceutical company with a rich legacy of over 100 years of scientific expertise, pioneering in pharmaceuticals that improve countless lives globally.

Products

Cardiovascular

Bempedoic acid and Bempedoic acid/Ezetimibe Combination: Approved in the EU, aimed at treating hypercholesterolemia and reducing cardiovascular risk.

Edoxaban (Lixiana®/SAVAYSA®): Oral, once-daily anti-coagulant product.

Oncology

Datopotamab Deruxtecan: A therapy for patients with advanced non-squamous non-small cell lung cancer, recently validated in the EU.

ENHERTU®: Launched for patients with HER2 positive unresectable or metastatic breast cancer in the US and Japan.

Other Therapeutics

Efient® (Prasugrel): An oral antiplatelet agent for preventing atherothrombotic events.

Rezaltas®: A high-affinity ARB/long-acting calcium antagonist compound.

Inavir®: An anti-influenza virus agent.

Memary®: Launched for the treatment of Alzheimer's disease.

CANAGLU® Tablets: For the treatment of Type 2 Diabetes Mellitus.

Key Features of Products

Bempedoic Acid: Lowers LDL cholesterol efficiently, reducing cardiovascular risk.

Edoxaban: Offers stroke prevention in patients with atrial fibrillation and VTE treatment.

Efient® (Prasugrel): Efficient in antiplatelet therapy to prevent heart-related events.

Recent Developments

Product Launches & Approvals

2021: Conditional approval of the first oncological product in Europe.

2020: Bempedoic acid and the combination with ezetimibe were introduced into European markets.

2023: A new affiliate opened in Canada.

New Product Features

Enhancement of cardiovascular product range with bempedoic acid treatments.

Partnerships and Growth

2019: Agreement with Esperion for the marketing of bempedoic acid through Europe.

2024: Investment of approximately one billion Euros in Germany to develop the Pfaffenhofen site into an international innovation center.

Summary

Daiichi Sankyo Europe GmbH, as a leading global pharmaceutical entity, emphasizes creating innovative therapeutic solutions across cardiology and oncology segments. The company continues expanding through strategic partnerships and improving product lines to address unmet global medical needs, leveraging a strong historic base and forward-looking vision. It maintains its European stronghold at Munich, with an extensive network spanning over 14 countries, embedding itself as a core player in medical advancements in the region.